Home  »  Equity Investing   »  Why is Statera Biopharma, Inc. (STAB) experiencing...

Why is Statera Biopharma, Inc. (STAB) experiencing a decrease in premarket?

Statera Biopharma, Inc. (STAB) experienced a decrease of 8.48% in the premarket. However, the last trading session closed at $2.24 with an increase of 1.82%.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

Study of STAT-205 – How were the results?

On 20th December 2021, STAB announced that the first patient has been enrolled and randomly assigned, with several others in the process of being screened for an initial study looking at STAT-205 as a potential treatment for COVID-19-causing SARS-CoV-2 virus progression. Moreover, STAT-205 is an immune modulator that helps to manage immunological dysfunction by lowering inflammatory responses linked to cytokine production and modulating Th1/Th2 helper cells.

Now what?

The development of safe and effective therapies for those who catch COVID-19 is the next task now that vaccinations are widely available. Moreover, Statera Biopharma is one of the first companies to modulate immune system function to decrease elevated inflammatory responses associated with SARS-CoV-2 viral infections. By developing a cost-effective COVID-19 therapeutic therapy, the method has the potential to improve outcomes for numerous patients and change the pandemic landscape. Lastly, the company is ecstatic that the first patient in the STAT-205 clinical trial has been randomized at the site.

Clinical Hold on Entolimod – Here’s the new update

On 1st December 2021, STAB announced that the US Food and Drug Administration (FDA) has withdrawn the clinical hold on Entolimod research and development efforts in acute radiation syndrome. Statera wants to examine ongoing development requirements and medical needs for Entolimod based on results demonstrating efficacy and safety in acute radiation syndrome.

Furthermore, STAB is launching an oncology and hematology development program based on the promise that toll-like receptor 5 agonists like Entolimod have demonstrated in the treatment of neutropenia and anemia in cancer patients. In 2022, talks are underway with a prestigious American academic institution to begin the first research of Entolimod in this new area of concentration.

Now what?

The company is delighted that the FDA’s clinical retain queries have indeed been effectively solved, enabling them to proceed the patient care in ARS and discover different hints for Entolimod in hematology, particularly care of neutropenia and anemia in cancer patients. As part of the aim to introduce the new generation of immunotherapies that tackle critical healthcare problems, STAB looks forward to expediting the research of Entolimod.

Leave a Comment

Your email address will not be published.

Related Posts